


# Radiopharmaceutical therapy controls symptoms and reduces medications in insulinoma patients

February 13 2024



62-year-old female patient who received 3 [<sup>90</sup>Y]Y-DOTATOC and 1 [<sup>177</sup>Lu]Lu-DOTATOC therapy cycles (total activity, 26.7 GBq) and benefited more than 15 of 18 months of observation. Baseline CT scan (A) and intratherapeutic [<sup>90</sup>Y]Y-DOTATOC SPECT/CT of second therapy cycle show

multiple liver metastases (B). CT scan after second therapy cycle shows partial tumor response with significantly reduced tumor burden according to RECIST 1.1 (C). Intratherapeutic [ $^{90}\text{Y}$ ]Y-DOTATOC SPECT/CT of fourth therapy cycle (D) shows reduced [ $^{90}\text{Y}$ ]Y-DOTATOC uptake in liver metastases compared with [ $^{90}\text{Y}$ ]Y-DOTATOC SPECT/CT of second therapy cycle (B), which also indicates treatment response. Credit: L Friebe and MT Freitag et al., University Hospital Basel, Basel, Switzerland

Peptide receptor radionuclide therapy (PRRT) is effective for clinical control of symptomatic metastatic insulinomas, according to new research [published](#) in *The Journal of Nuclear Medicine*. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80% of patients had long-lasting symptom control, and nearly 60% were able to reduce the use of other drugs to treat the disease.

Metastatic insulinoma is a rare malignant neuroendocrine tumor characterized by inappropriate insulin secretion. This results in life-threatening [hypoglycemia](#), which is often difficult to treat. The severity of symptoms can range from mild to life-threatening hypoglycemic events, leading to coma and death. Most insulinomas are benign, but approximately 6% develop metastases and are therefore considered malignant.

"Because of the rarity of the disease, the [treatment strategies](#) for malignant metastatic disease are ill-defined," stated Damian Wild, MD, Ph.D., nuclear medicine physician at University Hospital Basel, in Basel, Switzerland. "There is currently limited data available about the efficacy of PRRT in patients with malignant insulinomas. Our research aimed to evaluate whether PRRT could improve symptoms and if it had an impact on medication needed to control hypoglycemia."

The [retrospective study](#) included 26 patients with malignant insulinomas

who were treated with a total of 106 cycles of  $^{90}\text{Y}$ -DOTATOC or  $^{177}\text{Lu}$ -DOTATOC. A [scoring system](#) was used to quantify the severity and frequency of hypoglycemic episodes, and the score before and after PRRT was analyzed. Information on medication needed to control hypoglycemia before and after PRRT was also collected, an overall and [progression-free survival](#) was recorded.

PRRT was effective in controlling hypoglycemia in 81% of the study population and enabled 58% of patients to reduce the use of other drugs to control hypoglycemic episodes, resulting in reduced potential drug side effects. Overall and progression-free survival were 19.7 and 11.7 months, respectively.

"Compared to the effectiveness of other drugs commonly used to control hypoglycemia, the results of PRRT are promising and will likely have an impact on guidelines for the treatment of metastatic insulinoma," noted Wild. "They also imply that PRRT is indicated at an earlier time point, for example as a first or second line of therapy, for the treatment of metastatic insulinomas."

**More information:** Liene Friebe et al, Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis, *Journal of Nuclear Medicine* (2023). [DOI: 10.2967/jnumed.123.265894](https://doi.org/10.2967/jnumed.123.265894)

Provided by Society of Nuclear Medicine and Molecular Imaging

Citation: Radiopharmaceutical therapy controls symptoms and reduces medications in insulinoma patients (2024, February 13) retrieved 28 April 2024 from <https://medicalxpress.com/news/2024-02-radiopharmaceutical-therapy-symptoms-medications-insulinoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.